NNC0519-0130

Phase 2Small molecule

Novo Nordisk

NNC0519-0130 is one of 86 small molecule programs targeting Overweight. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

OverweightCompleted

Chronic Kidney DiseaseRecruiting

Body WeightCompleted

OverweightPhase 1

Completed

Chronic Kidney DiseasePhase 2

Recruiting

Body WeightPhase 2

Completed

Competition

Competitive Landscape

172 competitors in Chronic Kidney Disease

#DrugCompanyPhaseTrials

Uloric

Takeda

Preclinical

2 2

Sovaldi

Gilead

Preclinical

1 3

Glucotrol

Pfizer

Preclinical

1 4

Vemlidy

Gilead

Preclinical

1 5

Lorelco

Sanofi

Preclinical

1 6

NNC0519-0130

Novo Nordisk

Phase 2

1 7

Activase

Flomax

Januvia

ZZydus Therapeutics Inc.

Preclinical

1 10

Baraclude

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Body Weight2 trials

A Research Study of the New Medicine NNC0519-0130 in Male Chinese Participants Living With Excess Body Weight

Active, not recruiting· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT07004322·20 enrolled

A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Help People With Excess Body Weight Lose Weight

Completed· Novo Nordisk logo

Novo Nordisk·Phase 2·NCT06326060·355 enrolled

Type 2 Diabetes2 trials

A Research Study of How Safe a New Medicine Called NNC0519 0130 is and to Test Its Effect in People Living With Excess Body Weight With or Without Type 2 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT06567041·82 enrolled

A Research Study of a New Medicine NNC0519-0130 in Healthy People, People With High Body Weight and People With Type 2 Diabetes.

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT05363774·161 enrolled

Overweight2 trials

A Research Study to Compare How Much of the Medicine NNC0519-0130 is in the Blood of People With Overweight or Obesity Who Receive 2 Preparations of the Medicine

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT06642571·46 enrolled

A Research Study Comparing Different Ways of Increasing the Dose of NNC0519-0130 in Participants With Overweight or Obesity

Recruiting· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT06718998·114 enrolled

Chronic Kidney Disease1 trial

A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease

Recruiting· Novo Nordisk logo

Novo Nordisk·Phase 2·NCT06717698·465 enrolled

Function1 trial

A Research Study Looking Into Blood Levels of the Medicine NNC0519-0130 in the Body in Participants With Normal or Reduced Kidney Function

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT06370819·36 enrolled

3 more indications

Menopause1 trial

A Research Study Looking Into the Effect of NNC0519-0130 on Blood Levels of a Birth Control Pill and Emptying of the Stomach in Women After Menopause

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT06513104·47 enrolled

Diabetes Mellitus, Type 21 trial

Investigation of the Safety and Efficacy of Once Weekly NNC0519-0130 in Participants With Type 2 Diabetes - a Dose Finding Study

Completed· Novo Nordisk logo

Novo Nordisk·Phase 2·NCT06326047·299 enrolled

Unspecified1 trial

A Research Study of a New Medicine NNC0519-0130 in Japanese and Non-Japanese Men

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT05870670·22 enrolled

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for NNC0519-0130. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — NNC0519-0130 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for NNC0519-0130. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novo Nordisk company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Novo Nordisk

NNC0519-0130

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Body Weight2 trials

Type 2 Diabetes2 trials

Overweight2 trials

Chronic Kidney Disease1 trial

Function1 trial

Menopause1 trial

Diabetes Mellitus, Type 21 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News